Les Recommandations Thérapeutiques Les Publications Résumés des Protocoles GERCOR Le Courrier du Gercor Les Newsletters Autres Protocoles : Résumés Plan Accueil Nous contacter Quitter dictionnaire médical

Les Publications
Communications orales ou par affiches dans des congrès avec comité de sélection en langue anglaise
Publications dans des revues avec comité de lecture en langue anglaise
Publications dans des revues avec comité de lecture en langue française
GERCOR : ASCO 2002

toutes les rubriques



GERCOR : ASCO 2002
Abstracts ASCO 2002
Abstracts ASCO 2002

- Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Davidson N, Mounedji-Boudiaf L, Andre T, Hopital Saint-Antoine, Paris, France; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Hospital Duran i Reynals, Llobregat, Spain; Hospital Vall d'Hebron, Barcelona, Spain; Royal Bournemouth Hospital, Bournmouth, UK; St Luke's Cancer Center, Royal Surrey County Hospital, Guildford, UK; Ospedale di Legnago, Legnago, Italy; Illawara Cancer Care Center, Wollongong, Australia; North Middlesex Hospital, London, UK; Sanofi-Synthelabo, Paris, France; Hopital Tenon, Paris, France. Oxaliplatin/5-FU/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC trial. Proc Am Clin Oncol 2002; 21:133a (abst 525).

- Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Quinaux E, Buyse M and de Gramont A. For the GERCOR Group, Paris France. Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose (LV hd) for 24 or 36 weeks in patients with dukes’ B2 and C colon cancer. first report of efficacy. Proc Am Clin Oncol 2002; 21:133a (abst 529).

- Maindrault F, Louvet C, Tournigand C, Gervais H, Mabro M, Artru P, Garcia ML, Andre T, Carola E, de Gramont A, Hopital St-Antoine, Paris, France; Hopital Tenon, Paris, France; Hopital de Senlis, Senlis, France. Leucovorin, 5-fluorouracil infusion and irinotecan (folfiri-3) in pretreated patients with metastatic colorectal cancer. Proc Am Clin Oncol 2002; 21:133a (abst 658).

- Artru P, Taieb J, Tournigand C, Louvet C, Hafraoui S, Paye F, Maindrault F, Parc R, Gayet B, Molitor JL, de Gramont A, Hopital St-Antoine, Paris, France; Inst Mutualiste Montsouris, Paris, France. FOLFOX7 / FOLFIRI (MIROX) Regimen as (neo)adjuvant chemotherapy for patients with resectable metastatic colorectal cancer : preliminary results Proc Am Clin Oncol 2002; 21:133a (abst 672).

- Gervais H, Artru P, Louvet C, Tournigand C, Maindrault F, Garcia M, de Gramont A, Hopital St-Antoine, Paris, France. Reintroduction of irinotecan in pretreated patients with metastatic colorectal cancer.Proc Am Clin Oncol 2002; 21:133a (abst 688).

- Tournigand C, Louvet C, Molitor JL, Dehni N, Sezeur A, Pigne A, Marpeau L, Cady J, Lejeune V, Garcia ML, de Gramont A, Hopital Saint-Antoine, Paris, France; Hopital des Diaconnesses, Paris, France; Clinique Geoffroy St-Hilaire, Paris, France; Hopital Charles Nicolle, Rouen, France. Consolidation intraperitoneal chemotherapy (IP) in advanced ovarian cancer (AOC) with pathological complete response (PCR) or with microscopical residual disease. A GERCOR study. Proc Am Clin Oncol 2002; 21:133a (abst 883).


Accueil | | Nous contacter
© 2002 Gercor
Sitemap